Mogamulizumab Q4week Dosing in Participants With R/R CTCL

Cutaneous T-Cell Lymphoma Refractory Clinical Trial

Official title: Open-Label, Phase 2 Study to Assess the Safety of Mogamulizumab Given Every 4 Weeks Following Induction in Participants With Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL)

Status Active, not recruiting

Clinical Trial Summary

This is an open-label, multicenter, Phase 2 study to evaluate the safety and tolerability of mogamulizumab given Q4W following initial weekly induction in adult participants with relapsed/refractory MF and SS subtypes of CTCL. The study is composed of a 28-day Screening Period during which participants are screened for entry into this study, followed by a treatment period of up to 2 years from Cycle 1 Day 1.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Cutaneous T-Cell Lymphoma Refractory
• Cutaneous T-Cell Lymphoma, Relapsed
• Lymphoma
• Lymphoma, T-Cell
• Lymphoma, T-Cell, Cutaneous
• Lymphoma, T-Cell, Peripheral

• NCT number: NCT04745234
• Study type: Interventional
• Source: Kyowa Kirin Co., Ltd.
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: August 16, 2021
• Completion date: May 2025